When Hope Lancaster Colquhoun was prescribed Mounjaro and instantly shed the pounds, the jab felt like a 'lifeline'. But her ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily ...

Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 ...

A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...